CD19 and non-small cell lung carcinoma: Subsequently, a significant elevation in Tregs cells (CD4+ FOXP3+) and a reduction in effector cells (CD8+/CD19+) in the tumor tissues of NSCLC clinical specimens from 40 patients undergoing combined chemotherapy and immunotherapy was observed (Figure S9A–C, Supporting Information).